RG
AXDX

Redmile Group’s Accelerate Diagnostics AXDX Stock Holding History

Redmile Group’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,000
Closed -$215K – 49
2015
Q4 		$215K Buy
+1,000
New +$183K 0.02% 55

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Redmile Group's AXDX Position: Q1 2016 in Review

Redmile Group sold out of Accelerate Diagnostics (AXDX) in Q1 2016, closing a stake of 1,000 shares — an estimated $215K sold.

Redmile Group first reported a position in AXDX in Q4 2015 and held it in 1 quarter. The position peaked at $215K in Q4 2015. 92 funds tracked by Wall St. Rank hold AXDX as of Q1 2016.

  • Redmile Group reported no remaining Accelerate Diagnostics position as of Q1 2016 after selling out during the quarter.
  • Redmile Group sold 1,000 Accelerate Diagnostics shares in Q1 2016, an estimated $215K.
  • Redmile Group first reported a position in Accelerate Diagnostics in Q4 2015 and held it in 1 quarter.
  • Redmile Group's Accelerate Diagnostics position peaked at $215K in Q4 2015.
  • 92 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2016.

Based on Redmile Group's 13F filing for Q1 2016, filed 16 May 2016.